SAG
ZBIO

SageView Advisory Group’s Zenas BioPharma ZBIO Stock Holding History

SageView Advisory Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$146 Buy
+4
New +$132 ﹤0.01% 2526

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

SageView Advisory Group's ZBIO Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Zenas BioPharma (ZBIO) in Q4 2025: 4 shares worth $146. The stake represents ﹤0.01% of the portfolio and ranks #2526 among its holdings.

118 funds tracked by Wall St. Rank hold ZBIO as of Q4 2025.

  • SageView Advisory Group held 4 shares of Zenas BioPharma worth $146 as of Q4 2025.
  • Zenas BioPharma was a new SageView Advisory Group position in Q4 2025.
  • Zenas BioPharma made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2526 holding.
  • 118 funds tracked by Wall St. Rank held Zenas BioPharma as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.